Last updated on October 2018

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)


Brief description of study

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Clinical Study Identifier: NCT02576574

Contact Investigators or Research Sites near you

Start Over

Maritha Rossouw

Johese Clinical Research
Pretoria, South Africa
7.12miles

Lydia Dreosti

University of Pretoria Oncology Department
Pretoria, South Africa
9.96miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.